• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Titan Pharmaceuticals

Titan, Braeburn end commercialization deal for Probuphine drug-delivery implant

May 30, 2018 By Sarah Faulkner

Braeburn Pharmaceuticals

Titan Pharmaceuticals (NSDQ:TTNP) and Braeburn Pharmaceuticals said today that they plan to end a 2012 licensing agreement that gave Braeburn exclusive rights to commercialize Probuphine in the U.S. and Canada. Probuphine, which was developed using Titan’s ProNeura continuous drug-delivery tech, is an implant that can be placed in a patient’s upper arm in an outpatient office […]

Filed Under: Drug-Device Combinations, Featured, Pain Management, Pharmaceuticals, Wall Street Beat Tagged With: Braeburn Pharmaceuticals, Titan Pharmaceuticals

Shares in Titan Pharmaceuticals fall after Q3 miss

November 9, 2017 By Sarah Faulkner

Titan Pharmaceuticals

Shares in Titan Pharmaceuticals (NSDQ:TTNP) fell today after the company missed expectations on Wall Street with its third quarter results. The San Francisco, Calif.-based company posted a net loss of -$4.2 million on sales of $40,000 for the 3 months ended Sept. 30, for bottom-line loss of -60% on sales growth of 53.8% compared with the […]

Filed Under: Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Pain Management, Pharmaceuticals, Wall Street Beat Tagged With: Titan Pharmaceuticals

Titan Pharmaceuticals treats first Parkinson’s patient with subdermal implant

October 11, 2017 By Sarah Faulkner

Titan Pharmaceuticals

Titan Pharmaceuticals (NSDQ:TTNP) has treated the first patient in a Phase I/II trial of its ropinirole implant designed to treat the signs and symptoms of idiopathic Parkinson’s disease. Ropinirole is a dopamine agonist traditionally given orally to patients with Parkinson’s disease or restless leg syndrome. Titan’s ropinirole implant uses the company’s ProNeura drug delivery tech to […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Implants, Neurological, Pharmaceuticals, Wall Street Beat Tagged With: Titan Pharmaceuticals

Titan, Opiant partner to develop subcutaneous implant for opioid use disorder

October 5, 2017 By Sarah Faulkner

Titan Pharmaceuticals

Titan Pharmaceuticals (NSDQ:TTNP) and Opiant Pharmaceuticals (NSDQ:OPNT) announced this week that the companies are partnering to develop a subcutaneous implant to deliver an opioid antagonist. The pair said they plan to conduct a feasibility assessment of such an implant using Titan’s ProNeura sustained release technology. The goal of their collaboration is to devise a way to […]

Filed Under: Drug-Device Combinations, Featured, Implants, Pharmaceuticals, Wall Street Beat Tagged With: opiantpharmaceuticals, Titan Pharmaceuticals

Titan wins FDA nod to study Parkinson’s implant

August 24, 2017 By Sarah Faulkner

Titan Pharmaceuticals

Titan Pharmaceuticals (NSDQ:TTNP) said today that the FDA cleared the investigational new drug application for its ropinirole implant designed to treat the symptoms of Parkinson’s disease. The Phase I/II trial, which is slated to enroll 20 patients with idiopathic Parkinson’s disease, will transition patients taking oral ropinirole to Titan’s ropinirole implant for three months of treatment, […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Implants, Neurological, Pharmaceuticals, Wall Street Beat Tagged With: Titan Pharmaceuticals

Titan Pharmaceuticals misses estimates in Q2

August 10, 2017 By Sarah Faulkner

Titan Pharmaceuticals

Shares in Titan Pharmaceuticals (NSDQ:TTNP) fell yesterday after the pharmaceutical company missed expectations on Wall Street with its second quarter results. The San Francisco, Calif.-based company posted a net loss of -$3.5 million on sales of $77,000 for the 3 months ended June 30. In the same period last year, Titan posted profits of $11.9 million […]

Filed Under: Drug-Device Combinations, Featured, Implants, MassDevice Earnings Roundup, Pharmaceuticals, Wall Street Beat Tagged With: Titan Pharmaceuticals

Titan Pharmaceuticals lands $10m debt facility

July 31, 2017 By Sarah Faulkner

Titan Pharmaceuticals

Titan Pharmaceuticals (NSDQ:TTNP) said last week that it inked a $10 million venture loan and security deal with Horizon Technology Finance Corp. The first $7 million tranche was triggered after the groups inked a deal, Titan reported, and a second option of $3 million is available to the California-based company until March 31, 2018, contingent upon […]

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Implants, Pharmaceuticals, Wall Street Beat Tagged With: Titan Pharmaceuticals

Titan Pharmaceuticals partners for long-acting antimalarial implant

July 17, 2017 By Sarah Faulkner

Titan Pharmaceuticals

Titan Pharmaceuticals (NSDQ:TTNP) this month revealed a collaboration with the Walter Reed Army Institute of Research to evaluate the use of its ProNeura drug-delivery technology for the long-term prevention of malaria. The company is already working to develop its implant for an array of applications. Titan president & CEO Sunil Bhonsle told Drug Delivery Business News that this […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Implants, Pharmaceuticals Tagged With: Braeburn Pharmaceuticals, Titan Pharmaceuticals

FDA asks Titan for more info before clinical trial of ropinirole implant

February 28, 2017 By Sarah Faulkner

Titan Pharmaceuticals

Titan Pharmaceuticals (NSDQ:TTNP) said today that the FDA put a hold on the clinical trial of its ropinirole implant and told the company to submit more information to the federal watchdog. After it completed an initial review of the implant’s Investigational New Drug application, the FDA asked Titan for final release test data on its ropinirole […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Implants, Neurological, Wall Street Beat Tagged With: Titan Pharmaceuticals

Titan Pharmaceutical’s match-sized implant fights back against opioid addiction

February 14, 2017 By Sarah Faulkner

Titan Pharmaceuticals

The ongoing opioid crisis in the U.S. is harrowing – 91 Americans die every day from an opioid overdose, according to the Centers for Disease Control & Prevention. Companies are searching for innovative ways to deliver opioid maintenance treatment to patients that are hoping to get clean. Buprenorphine is a compound used for medication-assisted treatment, traditionally administered […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Implants, Wall Street Beat Tagged With: Centers for Disease Control & Prevention, Massachusetts Institute of Technology, Titan Pharmaceuticals

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS